Skip to main content
SpringerLink
Log in

Tumorassoziiertes hämolytisch-urämisches Syndrom (c-HUS)

  • Chapter
Kompendium Internistische Onkologie

  • 156 Accesses

Zusammenfassung

Das hämolytisch-urämische Syndrom (HUS) hat keine einheitliche Ätiologie. Unterschiedliche Ursachen wie Bakterientoxine (Boyce et al. 1995), Medikamente (Atkinson et al. 1983, Gordon u. Kwaan 1997) HIV-Infektionen (Ucar et al. 1994), Schwangerschaft (Ezra et al. 1996) oder Tumorkrankheit können seine Entstehung auslösen, und entsprechend variabel sind die jeweiligen Krankheitsverläufe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Atkinson K, Biggs JC, Hayes J et al (1983) Cyclosporin A-associated nephrotoxicity in the first 100 days after allogenic bone marrow transplantation: Three distinct syndromes. Br J Haematol 54:59–67

    Article  PubMed  CAS  Google Scholar 

  • Bell WR, Braine HG, Ness PM et al (1991) Improved survival in thrombotic thrombocytopenic purpura — hemolytic uremic syndrome. N Engl J Med 325: 398–403

    PubMed  CAS  Google Scholar 

  • Borghardt EJ, Nagel GA (1986) Behandlung des tumorassoziierten hämolytisch-urämischen Syndroms mit Protein A-Immunabsorption. In: Nagel GA, Sauer R, Schreiter HW (Hrsg) Aktuelle Onkologie Bd 28, S. 241–247

    Google Scholar 

  • Borghardt EJ, Kirchertz EJ, Helmchen U (1990) Protein A immunadsorption in cancer-associated hemolytic uremic syndrome. J Canc Res Clin Oncol Vol 116 Suppl 1:481

    Google Scholar 

  • Borghardt EJ, Kirchertz EJ (1993) Protein A immunadsorption in cancer-associated hemolytic uremic syndrome. Transfus Med Vol 3 Suppl. 1:21

    Google Scholar 

  • Borghardt EJ, Kirchertz EJ, Marten I, Fenchel K (1998) Protein A-immunoadsorption in chemotherapy-associated hemolytic-uremic syndrome. Transfus Sci Vol 19, Suppl, pp 5–7

    Article  PubMed  Google Scholar 

  • Boyce TG, Serdlow DL, Griffin PM (1995) Escherichia coli 0157:H7 and the hemolytic-uremic syndrome. N Engl J Med 333:364–368

    Article  PubMed  CAS  Google Scholar 

  • Charba D, Moake JL, Harris MA (1993) Abnormalities of von Willebrand multimers in drug-associated thrombotic microangiopathies. Am J Hematol 42: 268–277

    Article  PubMed  CAS  Google Scholar 

  • D’Souza RJ, Kwan ITC, Hendry BM et al (1997) Successful outcome of treating hemolytic uremic syndrome associated with cancer chemotherapy with immunoadsorption. Clin Nephrol 47:58–59

    PubMed  Google Scholar 

  • Ezra Y, Rose M, Eldor A (1996) Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies. Am J Hematol 51:1–6

    Article  PubMed  CAS  Google Scholar 

  • Furlan M, Robles R, Galbusera M et al (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Eng J Med 339:1578–1584

    Article  CAS  Google Scholar 

  • Gordon LI, Kwaan HG (1997) Cancer and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34:140–147

    PubMed  CAS  Google Scholar 

  • Kaplan AA (2000) Therapeutic apheresis for cancer-related hemolytic uremic syndrome. Ther Apher 4(3):201–206

    Article  PubMed  CAS  Google Scholar 

  • Korec S, Schein PS, Smith FP et al. (1986) Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 4:210–215

    PubMed  CAS  Google Scholar 

  • Krauss S, Sonoda T, Soloman A (1979) Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin-c. Cancer 43:1598–1603

    Article  PubMed  CAS  Google Scholar 

  • Lesesne JB, Rothschild N, Erickson B et al. (1989) Cancer-associated hemolyticuremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol Vol. 7 No 6:781–789

    PubMed  CAS  Google Scholar 

  • Moake JL (1994) Haemolytic-uraemic syndrome: basic science. Lancet 343:393–397

    Article  PubMed  CAS  Google Scholar 

  • Neild GH (1994) Haemolytic-uraemic syndrome in practice. Lancet 343:398–401

    Article  PubMed  CAS  Google Scholar 

  • Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393–397

    PubMed  CAS  Google Scholar 

  • Sheldon R, Slaugther D (1986) A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 58:1428–1436

    Article  PubMed  CAS  Google Scholar 

  • Shepard KV, Bukowski RM (1987) The treatment of thrombotic thrombocytopenic purpura with exchange transfusion, plasma infusions and plasma exchange. Semin Hematol 24:178–193

    PubMed  CAS  Google Scholar 

  • Snyder HWJr, Mittelman A, Oral A et al (1993) Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71:1882–1892

    Article  PubMed  Google Scholar 

  • Ucar A, Fernandez HF, Byrness JJ et al (1994) Thrombotic microangiopathy and retroviral infections: A 13-years experience. Am J Hematol 45: 304–309

    Article  PubMed  CAS  Google Scholar 

  • Valavaara R, Nordman E (1985) Renal complications of mitomycin-c therapy with special reference to the total dose. Cancer 55:47–50

    Article  PubMed  CAS  Google Scholar 

  • Westerholt S, Hartung T, Tollens M et al (2000) Inflammatory and immunological parameters in children with haemolytic uremic syndrome (HUS) and gastroenteritis — pathophysiological and diagnostic clues. Cytokine 12(6):822–827

    Article  PubMed  CAS  Google Scholar 

  • Zipfel PF, Skerka C, Caprioli J et al (2001) Complement factor H and hemolytic uremic syndrome. Int J Immunopharmacol 1(3):461–468

    Article  CAS  Google Scholar 

Download references

Authors
  1. E. J. Borghardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Borghardt, E.J. (2006). Tumorassoziiertes hämolytisch-urämisches Syndrom (c-HUS). In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_121

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_121

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation